{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4","value":"82.0"},{"groupId":"OG001","spread":"16.1","value":"82.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.6","value":"74.5"},{"groupId":"OG001","spread":"19.4","value":"71.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"80.2"},{"groupId":"OG001","spread":"11.0","value":"86.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.9","value":"84.3"},{"groupId":"OG001","spread":"8.0","value":"89.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Month 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"EQ-5D is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-consists of two components: a health state profile and an optional visual analogue scale (VAS). The EQ5D-VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. EQ-5D-VAS: range 0 to 100. A higher score indicates better self-reported health status. A positive change indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG001","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEAN","populationDescription":"Participants from the Safety Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 4, Month 3, and Month 6","title":"Change Over Time in EQ-5D Visual Analogue Scale (VAS) Score","type":"SECONDARY","unitOfMeasure":"scores on the scale"}